Biomarker modeling of Alzheimer's disease using PET-based Braak staging.

ABSTRACT: Gold-standard diagnosis of Alzheimer's disease (AD) relies on histopathological staging systems. Using the topographical information from [¹⁸F]MK6240 tau positron-emission tomography (PET), we applied the Braak tau staging system to 324 living individuals. We used PET-based Braak stage to model the trajectories of amyloid-β, phosphorylated tau (pTau) in cerebrospinal fluid (pTau₁₈₁, pTau₂₁₇, pTau₂₃₁ and pTau₂₃₅) and plasma (pTau₁₈₁ and pTau₂₃₁), neurodegeneration and cognitive symptoms. We identified nonlinear AD biomarker trajectories corresponding to the spatial extent of tau-PET, with modest biomarker changes detectable by Braak stage II and significant changes occurring at stages III-IV, followed by plateaus.

SUBMITTER: Therriault J 

PROVIDER: S-EPMC10154209 | biostudies-literature | 2022 Jun

REPOSITORIES: biostudies-literature